BackIbere Pharmaceuticals Overview

Ibere Pharmaceuticals Total Liabilities

Ibere Pharmaceuticals's total liabilities is $5.9M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$5.95M
↓ 51.09% YoYΔ $-6.21M vs prior year quarter

Peer trimmed avg / median

Loading

Ibere Pharmaceuticals Total Liabilities History

Loading

Ibere Pharmaceuticals vs. peers: Total Liabilities Comparison

Loading

Ibere Pharmaceuticals Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ibere Pharmaceuticals (IBER) FAQ

As of the most recent data (September 2022), IBER shows a total liabilities of $5.9M. That compares with $12M in the prior-year period — down 51.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IBER's total liabilities is now $5.9M (was $12M) — a 51.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Ibere Pharmaceuticals is outperforming or lagging.

Tracking IBER's total liabilities over time shows whether Ibere Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $5.9M That compares with $12M in the prior-year period — down 51.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Ibere Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $5.9M) with ownership activity and broader fundamentals.